Objective The role of allogenic stem cell transplantation (ASCT) is still debated in
myelofibrosis (MF). Methods A retrospective analyzed was performed to compare the …

Introduction: Allogeneic stem cell transplantation (SCT) is a curative option recommended
for patients with Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 …

Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …

Relapse after allogeneic haematopoietic stem cell transplantation (HSCT) is one of the key
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …

Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …

HSCT remains a highly relevant treatment option for myelofibrosis in the era of JAK
inhibitors. Recent advances may contribute to a refined definition of HSCT eligibility and …

Improvements in the field of allo-HSCT, the ability to improve patient's performance status
prior to transplant with JAK1/2 inhibitors and a more accurate disease risk stratification …

Allogeneic hematopoeitic cell transplantation (allo‐HCT) is the only curative treatment for
myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Introduction: The reported impact of gene mutations, including JAK2-V617F, other MPN
phenotypic drivers and additional cooccurring mutations on outcomes after allogeneic …